DENMARK – Global bioproduction company, 21st.Bio, has unveiled a new pilot plant facility at its Danish headquarters.

The plant, which merges proven industrial technology with fermentation capacity, providing a platform for clients to expedite their journey to scale in a manner that’s both risk-mitigated and cost-effective is set to boost the companies in upscaling bioproduction endeavors.  

“We make products, not projects; the focus is not solely on the number or value of projects but on the impact of the products brought to market,” Thomas Schmidt, co-founder, and CEO said.

Schmidt emphasized the pivotal role of biotech in addressing the escalating demand for high-quality food, emphasizing the inadequacy of traditional agricultural practices to meet global needs.

With our technology platform now being offered to that market, it is the first time that industrially proven technology is being applied to bulk production of foods.”

The pilot plant, boasting over 3,000 liters of fermentation capacity, is primed to bridge the gap between laboratory-scale fermentation and large-scale production.

Equipped to facilitate collaboration between 21st.Bio and customer teams, it aims to streamline the scaling process while minimizing risks associated with upscaling errors.

Positioned within proximity to the company’s strain development laboratories, the facility fosters seamless collaboration on enhancing production strains and fermentation processes.

Furthermore, 21st.Bio is gearing up to offer production technology for key proteins like dairy proteins to the market.

By providing world-class productivity and quality products, the company aims to empower innovators and fast-moving consumer goods (FMCGs) to focus on application development and manufacturing.

This initiative aligns with their broader vision of enabling numerous stakeholders to transition from innovation to industrial-scale production swiftly.

Denmark’s rich legacy in precision fermentation, epitomized by entities like Novo Nordisk and Novonesis, positions Europe as a trailblazer in bioproduction.

By leveraging leading-edge technology and expertise, the region stands poised to make substantial contributions to the global landscape.

In a recent conversation, Schmidt shed light on the company’s strategic move to grant access to its precision fermentation technology platform to ingredient manufacturers.

This development, forged in collaboration with Novozymes, marks a significant leap forward in large-scale production capabilities for manufacturers within the industry.

The initiative followed the successful scale-up of beta-lactoglobulin production, a pivotal milk protein, highlighting 21st.Bio’s commitment to revolutionizing the food industry with sustainable and cost-effective protein production technology.

Subscribe to our food and agriculture industry email newsletters that provide busy executives like you with the latest news insights and trends from Africa and the World. SUBSCRIBE HERE